<DOC>
	<DOCNO>NCT00054860</DOCNO>
	<brief_summary>The purpose study test safety HIV DNA vaccine ( EP HIV-1090 ) test whether vaccine stimulate immune system responses HIV uninfected people . This vaccine use part virus 's DNA cause HIV infection .</brief_summary>
	<brief_title>Safety Immune System Response HIV Vaccine ( EP HIV-1090 ) HIV Uninfected Adults</brief_title>
	<detailed_description>Epidemiological animal model data support hypothesis HIV specific cytotoxic T lymphocyte ( CTL ) responses contribute control clearance virus . Vaccines design specifically induce CTL response likely well suit protection HIV infection disease progression . EP HIV-1090 DNA vaccine compose 21 highly specific CTL epitope . The vaccine design optimize immune response people express one three HLA Class I antigen subtypes : HLA-A2 , -A3 , -B7 . This design predict induce immune response 85 % individual general population . There also helper T lymphocyte ( HTL ) facilitate epitope ( PADRE ) vaccine . The vaccine formulate water soluble polymer ( polyvinylpyrrolidone ) protect DNA facilitate cellular uptake . This study ass safety immune response different dos EP HIV-1090 healthy , HIV uninfected adult . Participants study randomize receive either one three different dos vaccine placebo . Participants receive vaccination placebo study entry Months 1 , 3 , 6 . Both vaccination placebo administer intramuscular injection . Participants follow 18 month 12 study visit . Each study visit include physical exam , medical history , blood urine test . Each participant four HIV test study . Women least five pregnancy test study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria HIV negative Positive one follow HLA supertypes : A2 , A3 , B7 Willing receive HIV test result Good general health Acceptable method contraception female reproductive potential Hepatitis B surface antigen negative Antihepatitis C virus antibody ( antiHCV ) negative negative HCV PCR antiHCV positive Exclusion Criteria HIV vaccine placebos prior HIV vaccine trial Immunosuppressive medication within 168 day prior first study vaccine administration Blood product within 120 day prior first study vaccine administration Immunoglobulin within 60 day prior first study vaccine administration Live attenuate vaccine within 30 day prior first study vaccine administration Investigational research agent within 30 day prior first study vaccine administration Subunit kill vaccine within 14 day prior first study vaccine administration Current tuberculosis prophylaxis therapy Active syphilis Serious adverse reaction vaccine . A person adverse reaction pertussis vaccine child exclude . Autoimmune disease immunodeficiency Unstable asthma Type 1 Type 2 Diabetes Mellitus Thyroid disease require treatment Serious angioedema within past 3 year Uncontrolled hypertension Bleeding disorder Malignancy unless surgically remove , opinion investigator , likely recur study period Seizure disorder require medication within past 3 year Asplenia Mental illness would interfere compliance protocol Other condition , judgment investigator , would interfere study Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV-1</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>Vaccines , DNA</keyword>
	<keyword>Dose-Response Relationship , Immunologic</keyword>
	<keyword>CD4-Positive T-Lymphocytes</keyword>
	<keyword>CD8-Positive T-Lymphocytes</keyword>
	<keyword>Epitopes</keyword>
</DOC>